IMMX
Immix Biopharma Inc

4,250
Mkt Cap
$142.34M
Volume
549,322.00
52W High
$4.60
52W Low
$1.34
PE Ratio
-5.38
IMMX Fundamentals
Price
$4.02
Prev Close
$4.23
Open
$4.30
50D MA
$2.85
Beta
1.04
Avg. Volume
780,871.74
EPS (Annual)
-$0.7641
P/B
16.91
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
HC Wainwright Reduces Earnings Estimates for Immix Biopharma
Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) - Research analysts at HC Wainwright cut their FY2025 earnings per share (EPS) estimates for shares of Immix Biopharma in a research report issued on...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
Immix Biopharma (NASDAQ:IMMX) Announces Earnings Results, Misses Expectations By $0.05 EPS
Immix Biopharma (NASDAQ:IMMX - Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate...
MarketBeat·11d ago
News Placeholder
Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?
Zacks·6mo ago
News Placeholder
IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips IMMX stock results show that Immix Biopharma missed analyst estimates for earnings per share the fourth quarter of 2023. The post IMMX...
InvestorPlace·2y ago
News Placeholder
Immix Biopharma, Inc. (NASDAQ:IMMX) Sees Large Growth in Short Interest
Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) saw a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 316,600 shares, a...
Zolmax·2y ago
News Placeholder
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) ( ImmixBio , Company , We or Us or IMMX ), a clinical-stage biopharmaceutical company trailblazing...
Globe Newswire·2y ago
News Placeholder
Immix Biopharma Announces Be Proactive in AL AL Amyloidosis Awareness Initiative
Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words Immix Biopharma Announces Be Proactive in AL AL Amyloidosis Awareness...
Globe Newswire·2y ago
News Placeholder
Immix Biopharma 12 Month Review Progress Update
LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced...
Globe Newswire·2y ago
News Placeholder
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
European Orphan Drug Designation ( ODD ) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for EU...
Globe Newswire·2y ago
News Placeholder
Immix Biopharma 5.5M share priced at $2.71
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago

Latest IMMX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.